Skip to main content

Posters

March 02, 2019
This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Background: A survey was carried out to investigate the relative importance of antipsychotic medication efficacy and perceived side effect burden and their impact on a patient’s decision to…
March 02, 2019
This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Background: There is limited literature on treatment patterns, healthcare resource utilization (HRU) and costs among patients who transition from paliperidone palmitate once-monthly (PP1M) to…
March 02, 2019
Treatment-resistant schizophrenia (TRS) occurs in up to 30% of patients with schizophrenia and is defined as the persistence of positive symptoms despite ≥2 trials of antipsychotic (AP) medications at adequate doses and duration with documented adherence. Patients may be treatment resistant at the…
March 02, 2019
Background: Tardive dyskinesia (TD) is associated with antipsychotics. To date, predictive models assessing the clinical characteristics on TD risk have not been developed and validated in the US population. Objective: To develop a prediction model identifying factors associated with TD occurrence.
March 02, 2019
Background: Lumateperone is a first-in-class agent in development for schizophrenia that acts synergistically through serotonergic, dopaminergic and glutamatergic systems.
March 02, 2019
Background: In the 12-week ARM-TD and AIM-TD studies, the odds of response to deutetrabenazine treatment were higher than the odds of response to placebo at all response levels. Deutetrabenazine was associated with low rates of overall adverse events and discontinuation. Objective: To evaluate long…
March 02, 2019
Objective: To evaluate the long-term safety and tolerability of once-daily valbenazine in adults with tardive dyskinesia (TD).
March 02, 2019
Introduction: RBP-7000 is a subcutaneously administered, once-monthly, extended-release depot formulation of risperidone designed to achieve therapeutic concentrations without supplemental oral dosing.
March 02, 2019
Background: Medication non-adherence is common for patients with schizophrenia. Decreasing dosing frequency of patients adequately treated with once-monthly paliperidone palmitate (PP1M) to once-every-three-month paliperidone palmitate (PP3M) may lead to better adherence and outcomes. Objectives:…
March 02, 2019
Background: This post hoc analysis evaluated the trajectory of clinical symptoms and illness severity of outpatients with schizophrenia receiving ongoing long-acting injectable aripiprazole lauroxil (AL) for up to 2 years.
Back to Top